The Zhitong Finance App learned that according to the latest data from the Hong Kong Stock Exchange, on September 3, Jinfang Pharmaceutical-B (02595) experienced changes in its inventory, with a total market value of HK$1,955 billion, accounting for 19.65%. The company's shareholders deposited 43.7309 million shares in Standard Chartered Bank (Hong Kong), increasing their shareholding ratio by 12.44%.

Jingfang Pharmaceutical previously announced that GFH375 has entered the first-line phase II study to treat KRAS G12D mutant advanced non-small cell lung cancer (NSCLC), including three treatment options: monotherapy, combined EGFR monoclonal antibody (cetuximab), or combination chemotherapy (pemetrexed).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.